Trial Profile
Efficacy and Safety of Nivolumab in Metastatic Renal Cell Cancer Patients - Japanese Real-World Data Through Clinical Chart Review
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.
- 05 Jul 2018 New trial record